These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32293349)

  • 41. p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.
    Gruber M; Ferrone L; Puhr M; Santer FR; Furlan T; Eder IE; Sampson N; Schäfer G; Handle F; Culig Z
    Endocr Relat Cancer; 2020 Mar; 27(3):187-198. PubMed ID: 31951590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Wnt signaling promotes androgen-independent prostate cancer cell proliferation through up-regulation of the hippo pathway effector YAP.
    Seo WI; Park S; Gwak J; Ju BG; Chung JI; Kang PM; Oh S
    Biochem Biophys Res Commun; 2017 May; 486(4):1034-1039. PubMed ID: 28366633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
    Zhu J; Qin P; Cao C; Dai G; Xu L; Yang D
    Oncol Rep; 2021 Mar; 45(3):963-974. PubMed ID: 33650661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intratumoral Heterogeneity Determines the Expression of mTOR-pathway Proteins in Prostate Cancer.
    Russo GI; Hennenlotter J; Vogel U; Kühs U; Wurm TM; Gerber V; Neumann T; Cimino S; Stenzl A; Todenhöfer T
    Dis Markers; 2019; 2019():1296865. PubMed ID: 31885728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1.
    Chen L; Chen Q; Kuang S; Zhao C; Yang L; Zhang Y; Zhu H; Yang R
    Cell Death Dis; 2019 Apr; 10(4):296. PubMed ID: 30931936
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.
    Machado-Neto JA; Lazarini M; Favaro P; Franchi GC; Nowill AE; Saad ST; Traina F
    Exp Cell Res; 2014 Jun; 324(2):137-45. PubMed ID: 24726915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
    Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
    Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors.
    Aguennouz M; Polito F; Visalli M; Vita G; Raffa G; Oteri R; Ghazi B; Scalia G; Angileri FF; Barresi V; Caffo M; Cardali S; Conti A; Macaione V; Bartolotta M; Giorgio RD; Germanò A
    Cancer Treat Res Commun; 2020; 24():100203. PubMed ID: 32777750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secreted frizzled-related protein 5 suppresses aggressive phenotype and reverses docetaxel resistance in prostate cancer.
    Xu Q; Lü Z; Wang X; Zhu Q; Wu H
    J Investig Med; 2019 Aug; 67(6):1009-1017. PubMed ID: 30787036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
    Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
    Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
    Kim TD; Jin F; Shin S; Oh S; Lightfoot SA; Grande JP; Johnson AJ; van Deursen JM; Wren JD; Janknecht R
    J Clin Invest; 2016 Feb; 126(2):706-20. PubMed ID: 26731476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ERK1 indicates good prognosis and inhibits breast cancer progression by suppressing YAP1 signaling.
    Yu S; Zhang M; Huang L; Ma Z; Gong X; Liu W; Zhang J; Chen L; Yu Z; Zhao W; Liu Y
    Aging (Albany NY); 2019 Dec; 11(24):12295-12314. PubMed ID: 31848326
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FFAR1-and FFAR4-dependent activation of Hippo pathway mediates DHA-induced apoptosis of androgen-independent prostate cancer cells.
    Wang J; Hong Y; Shao S; Zhang K; Hong W
    Biochem Biophys Res Commun; 2018 Nov; 506(3):590-596. PubMed ID: 30366669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
    Mu H; Xiang L; Li S; Rao D; Wang S; Yu K
    J Cell Biochem; 2019 Apr; 120(4):4987-4997. PubMed ID: 30302800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aspalathin-rich green Aspalathus linearis extract suppresses migration and invasion of human castration-resistant prostate cancer cells via inhibition of YAP signaling.
    Huang SH; Kao YH; Muller CJF; Joubert E; Chuu CP
    Phytomedicine; 2020 Apr; 69():153210. PubMed ID: 32217447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
    Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
    Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
    Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.